For Trp53−/−;Brca1−/−, survival was extended to 97 days (p = 0.0003 compared to Trp53−/−), whilst the longest survival was seen with Trp53−/−;Brca2−/− tumours (median 113 days), which was significantly longer than both Trp53−/− and Trp53−/−;Brca1−/− (p < 0.0001 for both comparisons). The gene discussed is BRCA1; the disease is neoplasm.